Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

2.
3.

Ropinirole therapy for Parkinson's disease.

Pahwa R, Lyons KE, Hauser RA.

Expert Rev Neurother. 2004 Jul;4(4):581-8. Review.

PMID:
15853577
4.

The safety of ropinirole, a selective nonergoline dopamine agonist, in patients with Parkinson's disease.

Schrag AE, Brooks DJ, Brunt E, Fuell D, Korczyn A, Poewe W, Quinn NP, Rascol O, Stocchi F.

Clin Neuropharmacol. 1998 May-Jun;21(3):169-75.

PMID:
9617508
5.

Ropinirole 24-hour prolonged release and ropinirole immediate release in early Parkinson's disease: a randomized, double-blind, non-inferiority crossover study.

Stocchi F, Hersh BP, Scott BL, Nausieda PA, Giorgi L; Ease-PD Monotherapy Study Investigators.

Curr Med Res Opin. 2008 Oct;24(10):2883-95. doi: 10.1185/03007990802387130 . Epub 2008 Sep 2.

PMID:
18768106
6.

Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.

Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI.

Int J Clin Pract. 2009 Apr;63(4):613-23. doi: 10.1111/j.1742-1241.2009.02027.x. Epub 2009 Feb 16.

PMID:
19222614
7.

[Improvements in motor and non-motor symptoms in parkinson patients under ropinirole therapy].

Buchwald B, Angersbach D, Jost WH.

Fortschr Neurol Psychiatr. 2007 Apr;75(4):236-41. German.

PMID:
17427044
8.

Ropinirole is effective on motor function when used as an adjunct to levodopa in Parkinson's disease: STRONG study.

Mizuno Y, Abe T, Hasegawa K, Kuno S, Kondo T, Yamamoto M, Nakashima M, Kanazawa I; STRONG Study Group.

Mov Disord. 2007 Oct 15;22(13):1860-5.

PMID:
17618525
9.

[Clinical data of the prolonged-release formulation of ropinirole].

Jost WH, Bergmann L.

Fortschr Neurol Psychiatr. 2010 Mar;78 Suppl 1:S20-4. doi: 10.1055/s-0029-1245178. Epub 2010 Mar 1. Review. German.

PMID:
20195937
10.

A multicentre retrospective study of the clinical use of ropinirole in the treatment of Parkinson's disease: the ROPI-PARK study.

Valldeoriola F, Cobaleda S, Lahuerta J.

Clin Neurol Neurosurg. 2009 Nov;111(9):742-7. doi: 10.1016/j.clineuro.2009.07.018. Epub 2009 Sep 3.

PMID:
19733003
11.

Meta-analysis of the efficacy and tolerability of pramipexole versus ropinirole in the treatment of restless legs syndrome.

Quilici S, Abrams KR, Nicolas A, Martin M, Petit C, Lleu PL, Finnern HW.

Sleep Med. 2008 Oct;9(7):715-26. doi: 10.1016/j.sleep.2007.11.020. Epub 2008 Jan 28.

PMID:
18226947
12.

Sumanirole versus placebo or ropinirole for the adjunctive treatment of patients with advanced Parkinson's disease.

Barone P, Lamb J, Ellis A, Clarke Z.

Mov Disord. 2007 Mar 15;22(4):483-9.

PMID:
17115380
13.

Dopamine agonists in the treatment of early Parkinson's disease: a meta-analysis.

Baker WL, Silver D, White CM, Kluger J, Aberle J, Patel AA, Coleman CI.

Parkinsonism Relat Disord. 2009 May;15(4):287-94. doi: 10.1016/j.parkreldis.2008.07.004. Epub 2008 Sep 6.

PMID:
18774743
14.

[Ropinirole in the treatment of Parkinson's disease: an update].

Vivancos-Matellano F.

Rev Neurol. 2006 May 1-15;42(9):542-8. Review. Spanish.

15.

Linear pharmacokinetic behavior of ropinirole during multiple dosing in patients with Parkinson's disease.

Hubble J, Koller WC, Atchison P, Taylor AC, Citerone DR, Zussman BD, Friedman CJ, Hawker N.

J Clin Pharmacol. 2000 Jun;40(6):641-6.

PMID:
10868315
16.

A comparison of sumanirole versus placebo or ropinirole for the treatment of patients with early Parkinson's disease.

Singer C, Lamb J, Ellis A, Layton G; Sumanirole for Early Parkinson's Disease Study Group.

Mov Disord. 2007 Mar 15;22(4):476-82.

PMID:
17318839
17.

Development of dyskinesias in a 5-year trial of ropinirole and L-dopa.

Rascol O, Brooks DJ, Korczyn AD, De Deyn PP, Clarke CE, Lang AE, Abdalla M; 056 Study Group.

Mov Disord. 2006 Nov;21(11):1844-50.

PMID:
16958094
18.

Ropinirole, a non-ergoline dopamine agonist.

Jost WH, Angersbach D.

CNS Drug Rev. 2005 Autumn;11(3):253-72. Review.

19.

[Systematic evaluation on influence of dopaminergic therapy: on motor complications in Parkinson's disease].

Zhou MZ, Liu ZG, Chen W, Lu LX, Wu JY, Qi C.

Zhonghua Yi Xue Za Zhi. 2009 Feb 24;89(7):438-44. Chinese.

PMID:
19567089
20.

Safety and tolerability of pardoprunox, a new partial dopamine agonist, in a randomized, controlled study of patients with advanced Parkinson's disease.

Hauser RA, Bronzova J, Sampaio C, Lang AE, Rascol O, Theeuwes A, van de Witte SV; Pardoprunox Study Group.

Eur Neurol. 2009;62(1):40-8. doi: 10.1159/000216839. Epub 2009 Apr 30.

PMID:
19407454

Supplemental Content

Support Center